Nemaura Pharma Limited Awarded the Prestigious 2016 Frost & Sullivan Award for Best Practices in Enabling Technology Leadership in Transdermal Drug Delivery

LOUGHBOROUGH, England--()--Nemaura Pharma has been awarded the prestigious 2016 Frost & Sullivan award for best practices in Enabling Technology Leadership in the Transdermal Drug Delivery Industry.

“We are delighted and honoured to receive this accolade”

The analysts stated that, “Nemaura Pharma’s drug delivery technology has revolutionized the way drugs are delivered in the healthcare system.” They spoke highly of Nemaura's Memspatch liquid delivery system because it is highly accurate, easy to use, and patient-friendly. The Memspatch uses microneedle technology to insert several small needles no more than few millimetres into the skin. The dose is dispersed over a larger surface area than is possible with a single needle, facilitating faster absorption. The judges pointed out that Nemaura has overcome the problem of erratic dosing that has dogged traditional transdermal patches by adding an applicator to the system—this allows for 100% needle penetration.

“Conventional liquid vaccine has contamination and stability risks associated with it,” said Frost & Sullivan Senior Research Analyst Debarati Sengupta. “Nemaura Pharma has reformulated the liquid vaccine into a stable, solid dose formulation, without any loss of potency.” The Micro-Patch system works by inserting a super-sharp stainless steel needle into the outer layer of the skin. The needle then retracts completely, minimising the risk of stick injuries, and the solid dose formulation remains deposited in the skin. The judges noted that the system eliminates the need for cold-chain storage, which should lead to significant savings and does not require a specialist to use it to administer the drug.

“The solid and liquid microneedle-based drug delivery technologies (Memspatch and Micro-Patch) provide pain-free, minimally-invasive drug delivery with controlled drug dosage,” noted Debarati. “With superior drug absorption, reduced or minimal drug stability or dosage issues, this easy-to-use transdermal technology drives better patient compliance and outcomes. With its strong overall performance, Nemaura Pharma has earned Frost & Sullivan's 2016 Enabling Technology Leadership Award.”

The award was made after an in-depth evaluation by Frost & Sullivan analysts, including a review by a panel of industry experts. “We are delighted and honoured to receive this accolade,” said Dr Faz Chowdhury, CEO of Nemaura Pharma. “We have worked over several years to carefully integrate human factors into what we envisage will become the world's leading injectable devices for a very wide range of drugs, and we anticipate this will enable patients globally to benefit from less intrusive and more intuitive devices for the routine administration of vaccines and medicines.”

Notes for Editors.

About Nemaura Pharma Limited

A private specialist biotech company, Nemaura Pharma is strategically positioned to work with global pharmaceutical companies, as well as new biotechnology companies, to successfully bring both new and old drugs to patients in superior delivery formulations and systems. Ultimately, we aim to improve patient lifestyle and quality of life. Our advanced drug delivery systems are designed to increase the effectiveness and safety of therapeutic drugs, while also reducing complications due to patient non-compliance, and mitigating the side effects of less efficient delivery systems.

www.nemaura.co.uk

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the Global 1000, emerging businesses, the public sector and the investment community.

http://ww2.frost.com/

Cautionary Statement Regarding Forward Looking Statements.

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.

Contacts

Nemaura Pharma Limited
David Scott, + 44 1509 222 912
bd@nemaura.co.uk

Recent Stories

RSS feed for Nemaura Pharma Limited